BioTuesdays

Tag - CBAY

CymaBay-Logo
Markets

BTIG starts CymaBay at buy; PT $15

BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...

March 9, 2023
CymaBay
Markets

HCW ups CymaBay Therapeutics to buy; PT $9

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral,” with a price target of $9, citing a possible lifting of the clinical hold on seladelpar development in liver disease. The stock closed...

May 26, 2020
CymaBay
Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020
CymaBay
Markets

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

November 25, 2019
CymaBay
Markets

Roth ups CymaBay price target to $6

Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following...

August 12, 2016